The Latest Breaking News from Regeneron Pharmaceuticals Inc

Natural gas prices were range bound for the better part of the last decade, oscillating between $2 and $4 per million British thermal units (MMBtu) with the occasional spike outside that tight range.

Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 4.85% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 2.16% of all regular shares that are available for trading.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease. It's an area where Regeneron has much expertise.  One of its best-selling products, Eylea, is approved to treat…

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC).  Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…